Semaglutide — Research Reference

Semaglutide (marketed as Ozempic for type 2 diabetes and Wegovy for weight management) is a synthetic analogue of human glucagon-like peptide-1 (GLP-1), a hormone secreted by intestinal L-cells in response to food intake. Semaglutide shares approximately 94% structural homology with native GLP-1 and incorporates modifications — including C18 fatty acid conjugation and two amino acid substitutions — that extend its half-life from the native 2 minutes to approximately 7 days, enabling once-weekly subcutaneous dosing.

Quick Reference

Parameter	Reported Value
Full name	Semaglutide
Amino acids	31
Molecular weight	~4,114 Da
Half-life	~7 days (reported; enables once-weekly dosing)
Common reported doses	0.25 mg/week (starting) to 2.4 mg/week (maximum studied)
Administration route	Subcutaneous injection
Storage (pen/vial)	Refrigerator; in-use pen stable at room temperature up to 28 days
Regulatory status	Approved pharmaceutical (Ozempic, Wegovy) in multiple jurisdictions

Overview

Semaglutide was developed by Novo Nordisk and is approved as a pharmaceutical in numerous jurisdictions — as Ozempic for type 2 diabetes and Wegovy for weight management. This makes semaglutide distinct from many compounds on this site: it has an established clinical trial evidence base and is available as a licensed medicine, though it is also widely circulated as a research compound.

Semaglutide acts at the GLP-1 receptor (GLP-1R), a G protein-coupled receptor expressed in the pancreas, hypothalamus, brainstem, and other tissues. Key mechanisms investigated in research include:

Insulin secretion: Stimulates glucose-dependent insulin release from pancreatic beta cells
Glucagon suppression: Inhibits glucagon secretion, reducing hepatic glucose output
Gastric emptying: Slows gastric emptying, reducing post-meal blood glucose peaks
Appetite regulation: Acts centrally in the hypothalamus to promote satiety and reduce caloric intake

The STEP 1 clinical trial reported a mean weight loss of approximately 14.9% over 68 weeks at the 2.4 mg weekly dose in adults with obesity. Additional research has investigated cardiovascular risk reduction and other metabolic benefits.

Reported Protocols

Standard Clinical Escalation Protocol

Semaglutide is associated with pronounced gastrointestinal side effects at higher doses, and a gradual escalation protocol is standard in both clinical and research contexts to allow tolerability adaptation.

The dosing escalation studied in STEP trials and used in clinical practice:

Weeks 1–4: 0.25 mg once weekly (initiation dose; not intended for weight management effect)
Weeks 5–8: 0.5 mg once weekly
Weeks 9–12: 1.0 mg once weekly
Weeks 13–16: 1.7 mg once weekly
Week 17 onward: 2.4 mg once weekly (maintenance; Wegovy dose)

For diabetes management (Ozempic), the approved maintenance dose is 1–2 mg weekly. The 2.4 mg dose is approved specifically for weight management under the Wegovy indication.

Anecdotal research accounts frequently describe pausing escalation or remaining at a lower dose when GI side effects are intolerable. Slower escalation than the above schedule is also reported.

Injection Timing

Due to the 7-day half-life, once-weekly dosing is sufficient to maintain near-steady-state plasma concentrations. Consistent weekly injection timing is the standard approach.

Reported Effects

The following effects have been reported in clinical research and anecdotal accounts.

Weight Reduction

The STEP 1 trial (n = 1,961) reported a mean placebo-subtracted weight reduction of approximately 12.4% over 68 weeks at 2.4 mg weekly. Participants receiving 2.4 mg achieved a mean weight reduction of approximately 14.9%. The SELECT cardiovascular outcomes trial (2023) additionally reported a 20% reduction in major adverse cardiovascular events (MACE) in participants with overweight and established cardiovascular disease.

Appetite Suppression

Research has investigated semaglutide’s potential role in reducing food intake via central GLP-1 receptor activation in the hypothalamus and brainstem, which modulates reward pathways and satiety signalling. Anecdotal reports frequently describe marked reduction in appetite and food cravings.

Glycaemic Control

In type 2 diabetes research, semaglutide has demonstrated HbA1c reduction of approximately 1.5–1.8% across major trials. This represents a primary registered indication.

Cardiovascular Effects

The SUSTAIN-6 and SELECT trials investigated semaglutide for cardiovascular risk reduction and reported reductions in major adverse cardiovascular events in high-risk populations.

Reported Side Effects

Reported side effects in research and anecdotal accounts include the following.

Side Effect	Frequency Reported
Nausea	Very common, particularly during escalation
Vomiting	Common
Diarrhoea	Common
Constipation	Common
Abdominal discomfort	Common
Decreased appetite	Very common (also a primary effect)
Injection site reactions	Occasionally reported
Fatigue	Occasionally reported
Headache	Occasionally reported

Serious reported concerns:

Pancreatitis: An increased risk of acute pancreatitis has been reported with GLP-1 receptor agonists as a class. Persistent severe abdominal pain warrants medical evaluation.
Gallbladder disease: Cholelithiasis and cholecystitis have been reported, likely related to rapid weight loss.
Thyroid C-cell effects: Rodent studies showed thyroid C-cell hyperplasia and carcinoma. Human relevance has not been established. Semaglutide is contraindicated in individuals with personal or family history of medullary thyroid carcinoma or MEN2 syndrome in approved clinical contexts.
Diabetic retinopathy: Rapid improvement in glycaemic control has been associated with transient worsening of diabetic retinopathy in some trial participants.
Muscle mass loss: As with significant caloric restriction, lean mass loss has been reported alongside fat mass reduction.

Storage & Handling

Licensed Pharmaceutical Product (Ozempic / Wegovy)

Unused pens: Store in the refrigerator (2–8°C) until the expiry date
In-use pens: May be stored at room temperature (below 30°C) for up to 28 days
Do not freeze; do not expose to direct sunlight
Discard needle after each use; replace cap on pen after use

Research Compound (Lyophilized / Reconstituted)

Lyophilized: Refrigerator preferred; room temperature stable short-term; protect from light; avoid freeze-thaw cycles
Reconstituted: Refrigerate; use within 4–6 weeks; do not freeze

See the Reconstitution Guide for step-by-step instructions.

Frequently Asked Questions

Is semaglutide the same as Ozempic? Ozempic and Wegovy are brand names for semaglutide. Ozempic is approved for type 2 diabetes management at doses up to 2 mg weekly. Wegovy is approved for chronic weight management at 2.4 mg weekly. The active compound in both is semaglutide; the difference is the approved indication, dose ceiling, and prescribing criteria. Rybelsus is a third brand name for an oral semaglutide formulation approved for type 2 diabetes.

What is the difference between Ozempic and Wegovy? Both contain semaglutide. Ozempic is approved for type 2 diabetes at doses up to 2 mg weekly. Wegovy is approved for chronic weight management at 2.4 mg weekly. The active compound is identical; the indication, approved dose, and prescribing criteria differ.

How does semaglutide compare to tirzepatide? Tirzepatide (Mounjaro/Zepbound) is a GLP-1/GIP dual agonist. Head-to-head trial data (SURMOUNT-5, 2024) has reported greater weight reduction with tirzepatide at comparable doses. The two compounds share a similar GI side effect profile. Both have cardiovascular outcomes research underway. See the Tirzepatide page for further detail.

What happens if you stop taking semaglutide? Clinical trial data indicates that weight regain typically occurs following discontinuation, with participants regaining a substantial proportion of lost weight within one to two years. This reflects the chronic nature of obesity as a condition and the ongoing pharmacological support required to maintain weight loss.

Can semaglutide cause muscle loss? Significant caloric restriction, regardless of mechanism, is associated with loss of lean mass. Research is ongoing regarding the lean-mass-sparing potential of GLP-1 agents. Anecdotal researchers frequently describe resistance training and high protein intake as practical mitigating approaches.

Goals: Fat Loss · Metabolic Health · Appetite & Weight Management

Class: GLP-1 / GIP / Glucagon Agonists

Comparisons: Tirzepatide vs Semaglutide · Retatrutide vs Semaglutide

References & Further Reading

Wilding JPH, et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. PubMed →
Marso SP, et al. (2016). Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine, 375(19), 1834–1844. PubMed →
Lincoff AM, et al. (2023). Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. New England Journal of Medicine, 389(24), 2221–2232. PubMed →